Interleukin-7

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Interleukin-7
DrugBank Accession Number
DB11997
Background

Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Interleukin-based products
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Glycosylated recombinant human interleukin-7
  • IL-7
  • Interleukin 7 glycosylated
  • Interleukin-7 human recombinant
  • r-hIL-7
  • Recombinant human interleukin-7
  • SH-polypeptide-42
External IDs
  • CYT 107
  • CYT-107

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Interleukin-7 human recombinant is a recombinant format of IL-7, a growth factor for T-cells which is shown to help restore and maintain lymphocyte counts, including both CD4+ and CD8+ T-cells, increasing the numbers of functional T-cells. The exact mechanism of action behind this is currently unknown.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
418XB47Y71
CAS number
858376-81-5

References

General References
  1. Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmele T, Blood T, Morre M, Gregoire A, Mayo GA, Blood J, Durum SK, Sherwood ER, Hotchkiss RS: Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018 Mar 8;3(5). pii: 98960. doi: 10.1172/jci.insight.98960. [Article]
  2. Perales MA, Goldberg JD, Yuan J, Koehne G, Lechner L, Papadopoulos EB, Young JW, Jakubowski AA, Zaidi B, Gallardo H, Liu C, Rasalan T, Wolchok JD, Croughs T, Morre M, Devlin SM, van den Brink MR: Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood. 2012 Dec 6;120(24):4882-91. doi: 10.1182/blood-2012-06-437236. Epub 2012 Sep 25. [Article]
  3. Tredan O, Menetrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronese E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Perol D, Blay JY, Caux C: ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. Ann Oncol. 2015 Jul;26(7):1353-62. doi: 10.1093/annonc/mdv173. Epub 2015 Apr 7. [Article]
  4. RevImmune Announces Phase II Trial of the T-Cell Growth Factor CYT107 for COVID-19 [Link]
PubChem Substance
347911267
RxNav
1367202
Wikipedia
Interleukin_7

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentSevere Sepsis1
2CompletedTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Refractory, metastatic hormone-refractory Prostate cancer / Stage IV Prostate Cancer1
2CompletedTreatmentSevere Sepsis With Septic Shock1
2RecruitingTreatmentAdvanced Bladder Urothelial Carcinoma / Advanced Ureter Urothelial Carcinoma / Metastatic Bladder Urothelial Carcinoma / Metastatic Renal Pelvis Urothelial Carcinoma / Metastatic Ureter Urothelial Carcinoma / Metastatic Urethral Urothelial Carcinoma / Recurrent Renal Pelvis Urothelial Carcinoma / Recurrent Ureter Urothelial Carcinoma / Recurrent Urethral Urothelial Carcinoma / Stage III Bladder Cancer AJCC v8 / Stage III Renal Pelvis Cancer AJCC v8 / Stage III Ureter Cancer AJCC v8 / Stage III Urethral Cancer AJCC v8 / Stage IV Bladder Cancer AJCC v8 / Stage IV Renal Pelvis Cancer AJCC v8 / Stage IV Ureter Cancer AJCC v8 / Stage IV Urethral Cancer AJCC v8 / Stage IVA Bladder Cancer AJCC v8 / Stage IVB Bladder Cancer AJCC v8 / Unresectable Bladder Urothelial Carcinoma / Unresectable Renal Pelvis Urothelial Carcinoma / Unresectable Ureter Urothelial Carcinoma / Urothelial Carcinoma Bladder Recurrent1
2RecruitingTreatmentB Cell Lymphoma (BCL)1
2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Lymphocytopenia5
2RecruitingTreatmentMycobacterium Infections, Nontuberculous1
2TerminatedTreatmentBladder Cancer, Cancer / Breast Cancer / Malignant Neoplasm of Colon1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2TerminatedTreatmentSevere Sepsis With Septic Shock1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 20, 2016 21:09 / Updated on January 24, 2021 06:03